BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Nowadays there is no randomized trials for comparison the effectiveness and tolerability of different conditioning regimens.

Bendamustine is a unique chemotherapeutic agent that combines alkylating action of nitrogen mustard and the activity of purine antimetabolite. Bendamustine has shown its effectiveness for the treatment of patients with chronic lymphoproliferative diseases such as chronic lymphocytic leukemia and several indolent lymphomas. The literature also presents evidence of the effectiveness bendamustine in patients with Hodgkin's lymphoma who received multiple lines of prior chemotherapy, including high dose chemotherapy and transplantation of peripheral hematopoietic stem cells. There are also data of using bendamustine as a part of conditioning regimen.

In this context, it was planned a study for evaluation the safety and effectiveness of the BeEAC (bendamustine, etoposide, cytarabine, cyclophosphamide) conditioning regimen prior to autologous transplantation of peripheral hematopoietic stem cells for the treatment of relapsed/refractory malignant lymphomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
• Treatments: Bendamustine Hydrochloride; Cyclophosphamide; Cytarabine; Etoposide; Etoposide phosphate

Criteria

Inclusion Criteria:

1. Be willing and able to provide written informed consent for the trial

2. Be ≥ 18 years of age on day of signing informed consent

3. Eastern Cooperative Oncology Group (ECOG) < 2.

4. Relapsed/refractory malignant lymphoma patients with indications to autologous hematopoietic stem-cell transplantation

Exclusion Criteria:

1. Participation in another clinical trials

2. Clinically relevant heart disease:

• Myocardial infarction during previous 6 months

• Unstable angina during previous 3 months

• Congestive heart failure (III-IV NYHA)

• Clinically relevant ventricular arrhythmias

• corrected QT interval (QTc) > 460 мс on ECG (calculated using Frederics formula)

• Left ventricular ejection fraction ≤ 45% on Echocardiogram

• Atrial Hypotension (systolic pressure < 86 mmHg) or bradycardia (< 50 per minute, exclusion - drug-induced bradycardia)

• Uncontrolled arterial hypertension (systolic pressure > 170 mmHg or diastolic pressure > 105 mmHg)

3. Severe renal dysfunction (serum creatinine > 250 µmol/l)

4. Severe hepatic dysfunction (total bilirubin > 40 µmol/l)

5. Known history of Human Immunodeficiency Virus or active Hepatitis B and C

6. Psychiatric or substance abuse disorders that would interfere with the cooperation with the requirements of the trial

7. Hypersensitivity to investigational drugs

8. Pregnant or breastfeeding females or males and females with childbearing potential must be willing to use an adequate method of birth control (intrauterine device, vasectomy of female subjects' male partner, contraceptive rod implanted into the skin, combination method - (requires use of two of the following) diaphragm with spermicide, cervical cap spermicide, contraceptive sponge, condom, hormonal contraceptive)